Carcinoma, Bronchogenic D002283

Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Thoracic Neoplasms » Respiratory Tract Neoplasms » Lung Neoplasms » Bronchial Neoplasms » Carcinoma, Bronchogenic

Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Lung Neoplasms » Carcinoma, Bronchogenic

Diseases [C] » Respiratory Tract Diseases [C08] » Respiratory Tract Neoplasms » Lung Neoplasms » Bronchial Neoplasms » Carcinoma, Bronchogenic

Description

Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.   MeSH

Hierarchy View

Subtype Terms (2)

Carcinoma, Non-Small-Cell Lung
1254 drugs (269 approved, 985 experimental)

Small Cell Lung Carcinoma
403 drugs (135 approved, 268 experimental)


Approved Indicated Drugs (1)

Phase 1 Indicated Drugs (3)


Organization Involved with Phase 3 Indications (3)

Organization Involved with Phase 1 Indications (2)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.